ArriVent Biopharma Overview
- Year Founded
-
2021
- Status
-
Public
- Employees
-
77
- Stock Symbol
-
AVBP
- Share Price
-
$13.01
- (As of Friday Closing)
ArriVent Biopharma General Information
Description
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. The company focuses on advancing its lead product candidate, firmonertinib, for the treatment of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC), and developing a pipeline of novel therapeutics, including next-generation antibody-drug conjugates such as ARR-217 (MRG007), with an initial focus on solid tumors.
Contact Information
Website
www.arrivent.comCorporate Office
- 18 Campus Boulevard
- Suite 100
- Newtown Square, PA 19073-3269
- United States
Corporate Office
- 18 Campus Boulevard
- Suite 100
- Newtown Square, PA 19073-3269
- United States
ArriVent Biopharma Stock Performance
As of 13-Nov-2026, ArriVent Biopharma’s stock price is $13.01. Its current market cap is $673M with 51.7M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $13.01 | $13.07 | $11.36 - $35.83 | $673M | 51.7M | 1.29M | -$3.60 |
ArriVent Biopharma Financials Summary
As of 30-Sep-2026, ArriVent Biopharma has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 1,120,270 | 530,371 | 1,052,110 | |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (186,000) | (177,534) | (94,308) | (74,590) |
| Net Income | (174,070) | (166,308) | (80,488) | (69,333) |
| Total Assets | 417,089 | 333,169 | 274,942 | 163,098 |
| Total Debt | 256 | 14 | 176 | 317 |
ArriVent Biopharma Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
ArriVent Biopharma Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
ArriVent Biopharma Comparisons
Industry
Financing
Details
ArriVent Biopharma Competitors (4)
One of ArriVent Biopharma’s 4 competitors is Aclaris Therapeutics, a Formerly VC-backed company based in Wayne, PA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Aclaris Therapeutics | Formerly VC-backed | Wayne, PA | ||||
| PDS Biotechnology | Formerly VC-backed | Princeton, NJ | ||||
| Exelixis | Formerly VC-backed | Alameda, CA | ||||
| Puma Biotechnology | Corporation | Los Angeles, CA |
ArriVent Biopharma Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
ArriVent Biopharma Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
ArriVent Biopharma Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
ArriVent Biopharma ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
37.84 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
ArriVent Biopharma FAQs
-
When was ArriVent Biopharma founded?
ArriVent Biopharma was founded in 2021.
-
Where is ArriVent Biopharma headquartered?
ArriVent Biopharma is headquartered in Newtown Square, PA.
-
What is the size of ArriVent Biopharma?
ArriVent Biopharma has 77 total employees.
-
What industry is ArriVent Biopharma in?
ArriVent Biopharma’s primary industry is Drug Discovery.
-
Is ArriVent Biopharma a private or public company?
ArriVent Biopharma is a Public company.
-
What is ArriVent Biopharma’s stock symbol?
The ticker symbol for ArriVent Biopharma is AVBP.
-
What is the current stock price of ArriVent Biopharma?
As of 13-Nov-2026 the stock price of ArriVent Biopharma is $13.01.
-
What is the current market cap of ArriVent Biopharma?
The current market capitalization of ArriVent Biopharma is $673M.
-
Who are ArriVent Biopharma’s competitors?
Aclaris Therapeutics, PDS Biotechnology, Exelixis, and Puma Biotechnology are competitors of ArriVent Biopharma.
-
What is ArriVent Biopharma’s annual earnings per share (EPS)?
ArriVent Biopharma’s EPS for 12 months was -$3.60.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
